Hikma Launches Combined Pain Relief Drug Combogesic IV In US
The Paracetamol/Ibuprofen Infusion Launches After Regulatory Back And Forth
Hikma announced the launch of the pain relief solution in the US where it will be sold under the name Combogesic IV as part of a deal with Hyloris Pharmaceuticals.
You may also be interested in...
Hyloris has received US approval for its generic podofilox gel, previously referred to as HY-016.
Hyloris has announced US FDA approval for its Maxigesic IV innovative paracetamol/ibuprofen solution for infusion. The product is expected to launch in the US in early 2024 via marketing partner Hikma, under the name Combogesic IV.
Hyloris has submitted additional data to the US Food and Drug Administration about its value-added analgesic Maxigesic IV, following enquiries about potential extractable and leachable compounds expected to be present in the product due to the packaging.